CytoSorbents Reports Third Quarter 2025 Revenue of $9.5 Million
CytoSorbents Corporation reported third quarter 2025 revenue of $9.5 million, representing a 10% increase year-over-year. The company amended its credit agreement with Avenue Capital Group, gaining an additional $2.5 million in cash and extending the interest-only period through December 31, 2026, with a further $2.5 million available and a possible extension to June 30, 2027, contingent on DrugSorb-ATR FDA marketing approval. Proforma cash, cash equivalents, and restricted cash totaled $11.6 million as of September 30, 2025, assuming the additional term loan capital had been drawn, with total proforma debt at $17.5 million. CytoSorbents also implemented a Workforce and Cost Reduction Program, aiming to accelerate its path to cash-flow breakeven by the first quarter of 2026. The company submitted a DrugSorb-ATR De Novo pre-submission package to the FDA, with a meeting expected in late 2025 or early 2026 and a regulatory decision anticipated by mid-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000929638-25-004243), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.